Questions? Call 800-624-6242

| Items in cart [0]

PAPERBACK
price:\$43.50

## New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986) Board on Population Health and Public Health Practice (BPH)

### Citation Manager

. "7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

 Page 83

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

FIGURE 7.1 Calculation of potential health benefits.

relation to the age of anticipated vaccination, by whether any disease falls outside the target population, and by the ability to formulate a vaccine effective against all strains/types causing disease. Factors influencing the estimate of the proportion of vaccine preventable illness are discussed in relevant sections of Appendixes D-1 through D-19.

1. Calculate vaccine preventable illness (VPI) values for each disease/vaccine combination. In this analysis, VPI values are calculated from TDBVs using the estimate of the proportion of the disease burden that is potentially preventable. A more exacting approach is to estimate for each disease in each age group/morbidity category combination, the number of cases, complications, sequelae, or deaths that could theoretically be prevented annually (in a steady state of vaccine use) and then use IME values to calculate VPI values in a manner similar to that for deriving TDBVs as described in Chapter 4.

2. Calculate the possible reduction in morbidity and mortality (PRMM) for each vaccine. These figures represent vaccine preventable illness values adjusted for the predicted efficacy of the vaccine. For

 Page 83
 Front Matter (R1-R16) 1. Summary (1-18) 2. Priority Setting for Health-Related Investments: A Review of Methods (19-29) 3. Overview of the Analytic Approach (30-43) 4. Comparison of Disease Burdens (44-62) 5. Predictions of Vaccine Development (63-75) 6. Assessing the Likely Utilization of New Vaccines (76-81) 7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105) 8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120) 9. Findings, Conclusions, and Recommendations (121-142) Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148) Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158) Appendix C: The Burden of Disease Resulting from Diarrhea (159-169) Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177) Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185) Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196) Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207) Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222) Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240) Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250) Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266) Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274) Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286) Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298) Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307) Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318) Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328) Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337) Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356) Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375) Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389) Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402) Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411) Appendix F: Technical Notes (412-412) Appendix G: Biographical Notes on Committee Members (413-417) Appendix H: Additional Sources of Advice to the Committee (418-419) Appendix I: Contents of Supplement to Volume II (420-420) Appendix J: Preface to Volume I (421-422) Appendix K: Contents to Volume I (423-423) Index (424-432)